Pep-Therapy has now raised $2.9m to deliver peptide-based cancer drugs that further research from Université Pierre et Marie Curie, Institut Curie and Inserm.
Pep-Therapy, a France-based therapeutic peptide developer based on research from Université Pierre et Marie Curie, Institut Curie and Inserm, received €1.2m ($1.4m) in its second funding round today.
The round featured Seventure Partners’ Quadrivium 1 seed fund as well as private investor Bernard Majoie, the founding chairman of nonprofit cancer research organisation Fournier-Majoie Foundation for Innovation.
Founded in 2014, Pep-Therapy is working on oncological peptides that penetrate tumour cells to thwart interactions between the proteins within that sustain…